We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+3.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.91B
AUM Growth
+$61.2M
Cap. Flow
+$64.4M
Cap. Flow %
2.22%
Top 10 Hldgs %
30.43%
Holding
226
New
26
Increased
31
Reduced
48
Closed
30

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$41M
2
ABT icon
Abbott
ABT
+$37M
3
MRNA icon
Moderna
MRNA
+$32.5M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$29.2M
5
GILD icon
Gilead Sciences
GILD
+$26.5M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$60.5M
2
BDX icon
Becton Dickinson
BDX
+$22.1M
3
HUM icon
Humana
HUM
+$18.1M
4
TECH icon
Bio-Techne
TECH
+$16.1M
5
NVCR icon
NovoCure
NVCR
+$15.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.75%
2 Real Estate 2.99%
3 Industrials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
51
Humana
HUM
$45B
$15.7M 0.54%
37,341
-45,466
-55% -$18.1M
ASND icon
52
Ascendis Pharma A/S
ASND
$16B
$15.3M 0.52%
118,336
+22,090
+23% +$3.36M
WELL icon
53
Welltower
WELL
$168B
$14.5M 0.5%
203,083
– –
MRTX
54
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$14.4M 0.49%
83,784
– –
ONC
55
BeOne Medicines Ltd
ONC
$32.6B
$14.1M 0.48%
40,389
+12,109
+43% +$4.01M
DCPH
56
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$13.8M 0.47%
307,703
+246,333
+401% +$11.5M
ARNA
57
DELISTED
Arena Pharmaceuticals Inc
ARNA
$13.6M 0.47%
196,385
-56,586
-22% -$4.35M
ADPT icon
58
Adaptive Biotechnologies
ADPT
$3.68B
$13.6M 0.47%
337,722
+51,709
+18% +$2.8M
IQV icon
59
IQVIA
IQV
$38.4B
$13.5M 0.46%
69,866
-6,200
-8% -$1.16M
STRO icon
60
Sutro Biopharma
STRO
$416M
$13.1M 0.45%
57,382
-12,870
-18% -$3.05M
CRL icon
61
Charles River Laboratories
CRL
$11.1B
$12.5M 0.43%
43,074
+14,920
+53% +$4.15M
FATE icon
62
Fate Therapeutics
FATE
$291M
$12.4M 0.43%
150,343
-15,974
-10% -$1.53M
BPMC
63
DELISTED
Blueprint Medicines
BPMC
$11.9M 0.41%
122,699
– –
NVS icon
64
Novartis
NVS
$292B
$11.6M 0.4%
136,225
-8,300
-6% -$745K
MTD icon
65
Mettler-Toledo International
MTD
$29.2B
$11.3M 0.39%
9,800
– –
TPTX
66
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$11.3M 0.39%
119,324
– –
OHI icon
67
Omega Healthcare
OHI
$14.7B
$11.2M 0.39%
306,433
– –
VTR icon
68
Ventas
VTR
$46.6B
$11.1M 0.38%
208,108
– –
RARE icon
69
Ultragenyx Pharmaceutical
RARE
$2.46B
$11.1M 0.38%
97,480
– –
JAZZ icon
70
Jazz Pharmaceuticals
JAZZ
$15.8B
$11.1M 0.38%
67,456
– –
UTHR icon
71
United Therapeutics
UTHR
$25.7B
$10.6M 0.37%
63,513
– –
BDX icon
72
Becton Dickinson
BDX
$46.9B
$10.5M 0.36%
44,390
-90,626
-67% -$22.1M
KRTX
73
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$10.2M 0.35%
85,236
– –
ACH
74
Accendra Health
ACH
$261M
$10M 0.34%
266,023
– –
IONS icon
75
Ionis Pharmaceuticals
IONS
$9.06B
$9.73M 0.33%
216,371
+23,170
+12% +$1.29M
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Tekla Capital Management held 226 positions worth $2.91B, up 2.1% from $2.85B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Tekla Capital Management's Q1 2021 filing shows 26 new, 31 increased, 48 reduced and 30 closed positions. Its largest new stake was Universal Health Services: 71,323 shares worth $9.51M. The largest sale was Alexion Pharmaceuticals, an estimated $60.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2021 buy was Universal Health Services: 71,323 shares worth $9.51M.
  • Tekla Capital Management added most to Elevance Health in Q1 2021, an estimated $41M increase.
  • Tekla Capital Management's biggest Q1 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $60.5M.
  • Tekla Capital Management fully exited NovoCure in Q1 2021, selling an estimated $15.2M.
  • Tekla Capital Management's ten largest holdings make up 30% of its $2.91B portfolio in Q1 2021.
  • Tekla Capital Management opened 26 new positions and closed 30 in Q1 2021.
  • Tekla Capital Management's portfolio value rose 2.1% quarter-over-quarter to $2.91B.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.